Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.
Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.
The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.
Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.
The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.
For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.
Castle Biosciences (NASDAQ:CSTL) announced a study showcasing its DecisionDx-Melanoma test's predictive capabilities in cutaneous melanoma. The study, involving 438 patients, revealed that those classified as Class 1A (low risk) achieved a remarkable five-year recurrence-free survival rate of 95.8% and a distant metastasis-free survival rate of 99.2%. This underscores the test's role in aiding personalized treatment decisions and improving patient outcomes, with significant independent predictive value over traditional staging methods.
Castle Biosciences, Inc. (Nasdaq: CSTL) will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, Nov. 18, 2021, at 9:30 a.m. Eastern time. CEO Derek Maetzold and CFO Frank Stokes will share insights about the company’s innovative diagnostics aimed at improving patient outcomes. Live audio webcasts will be available on the company’s website, with replays accessible for two weeks post-event. Castle specializes in personalized genomic information for better treatment decisions in cancers like melanoma.
Castle Biosciences, Inc. (CSTL) reported a 54% revenue increase in Q3 2021, totaling $23.5 million compared to Q3 2020. The company is on track to meet its 2021 revenue guidance of $89-93 million. Despite a 16% decline in melanoma diagnoses versus pre-COVID levels, test report volume rose to 7,352. Gross margins were 77.9%, with adjusted gross margins at 80.9%. Cash reserves stand at $363 million. Strategic acquisitions, including Cernostics, are expected to broaden market reach and support future growth.
Castle Biosciences (CSTL) released a study validating the i31-GEP SLNB algorithm, which integrates the DecisionDx®-Melanoma gene expression profile with clinicopathologic features to improve predictions of sentinel lymph node biopsy (SLNB) positivity in melanoma patients. The algorithm demonstrated a high correlation (0.999) between predicted and observed SLN positivity rates, with a sensitivity of 95.1%. This advancement may help clinicians identify patients who can safely avoid SLNB, thus optimizing treatment strategies and potentially reducing unnecessary procedures.
Castle Biosciences, Inc. (CSTL) has partnered with ModMed to create an interface for their dermatologic electronic health record system, EMA®. This integration allows dermatologic clinicians to order Castle's skin cancer tests directly from patient records, streamlining their workflow. The DecisionDx® suite of tests, which provides actionable information for melanoma and skin cancer management, will be accessible within EMA. This initiative aims to improve patient care and is expected to be operational by the end of 2021.
Castle Biosciences (NASDAQ: CSTL) has enhanced its DecisionDx-Melanoma test by integrating the new i31-GEP for Risk of Recurrence (i31-ROR) algorithm. This innovation aims to predict five-year outcomes for melanoma-specific survival, distant metastasis-free survival, and recurrence-free survival, improving treatment precision for patients. The company previously launched i31-SLNB to provide risk assessments for sentinel lymph node positivity. Both algorithms utilize tumor-specific data, with validation from over 5,700 samples, promising better patient management and treatment pathways.
Castle Biosciences (Nasdaq: CSTL) has announced new data validating its DecisionDx® DiffDx™-Melanoma test as an accurate tool for diagnosing challenging melanocytic lesions. Highlighted at the ASDP Annual Meeting (Oct. 20-24), the study demonstrated a high 96% sensitivity and 92.2% specificity, showcasing the test's reliability. When combined with myPath® Melanoma, the diagnostic workflow increased actionable results from 78% to 99%. This advancement enhances diagnostic confidence, improving patient care in uncertain cases.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
What does Castle Biosciences specialize in?
When was Castle Biosciences founded?
What types of cancer does Castle Biosciences have tests for?
What are some of Castle Biosciences' notable products?
Is Castle Biosciences involved in research for new diagnostic tests?
Where can I find more information about Castle Biosciences and its products?
What is the primary mission of Castle Biosciences?
Does Castle Biosciences collaborate with other entities?
What is Castle Biosciences' financial condition?
How does Castle Biosciences contribute to cancer care?
